List view / Grid view
22 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Sanofi and Bioverativ Inc., have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ...
6 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have found that polymer and hybrid silica-coated microcapsules are efficient in genome-editing...
26 June 2017 | By Naghmana Bajwa MD | Global Medical Affairs Haematology Lead | Shire
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
20 June 2016 | By Victoria White, Digital Content Producer
Freeline is developing and commercialising gene therapies for bleeding and other life threatening or debilitating disorders...
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...
Send this to a friend
Follow: